• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Intratumoral Therapy with Cytokine Gene-Modified Dendritic Cells in Murine Lung Cancer Models

        互联网

        694
        The central importance of functional host professional antigen-presenting cell (APC) in the immune response against cancer has been well-defined (1 ). Dendritic cells (DC) are highly specialized professional APC with potent capacity to capture, process, and present antigen to T cells (2 ). Unfortunately, tumor cells interfere with host DC maturation and function (3 ). To circumvent tumor-mediated inhibition of DC maturation and function in vivo, DC that have undergone cytokine-stimulated maturation ex vivo have been effectively utilized in clinical trials and murine cancer models (4 8 ) Antigen-specific cytotoxic T lymphocytes (CTL) responses have been achieved utilizing ex vivo antigen-pulsed DC (5 ,9 11 ). Additionally, novel tumor antigen-delivery systems utilizing cytokine gene-transduced tumor cells and DC (4 ,7 ) or fusion of tumor cells with DC have resulted in induction of antitumor immunity (12 ,13 ). Delivery of tumor antigens by ex vivo stimulated DC has been shown to be superior to purified peptides in avoiding CTL tolerization (14 ). Vaccination with multiple tumor antigens may be superior to the use of a single epitope (15 ,16 ) and these responses can be further enhanced by the co-administration of immune-potentiating cytokines (4 ,7 ). We have demonstrated previously that interleukin (IL)-7-transduced tumor cells administered intratumorally in conjunction with DC elicit potent antitumor responses in a murine model of established lung cancer (7 ).
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序